Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.67 |
| ▸ | FNTB | P49356 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950799 | 1.00 | FNTA (0.67) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10143955 | 0.89 | FNTA (0.60) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22624833 | 0.89 | FNTA (0.70) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1949783 | 0.86 | FNTA (0.67) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1949785 | 0.86 | FNTA (0.67) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22624760 | 0.86 | FNTA (0.67) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14011737 | 0.86 | FNTA (0.79) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22611887 | 0.86 | FNTA (0.79) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22624733 | 0.85 | FNTA (0.60) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11814348 | 0.85 | MAPT (0.57) | FNTAFNTBALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2151446-B1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORP (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2151445-B1 | Process for the preparation of bidentate Schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORP (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8338613-B2 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110137043-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | TELENE S.A.S. (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110065925-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | TELENE S.A.S. (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2151446-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | Telene SAS (FR) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151445-A1 | Process for the preparation of bidentate Schiff base ruthenium cataysts containing a saliclyldimine-type ligand | Telene SAS (FR) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137043-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | SPR, LIG4, SUCLA2 | FNTA 1072/4885FNTB 2122/4885ALDH1A1 1371/4885 |
| US-20110065925-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | SPR, LIG4, SUCLA2 | FNTA 1072/4885FNTB 2122/4885ALDH1A1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.